• 1
    Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007; 25: 1908-1915.
  • 2
    Roboz GJ. Treatment of acute myeloid leukemia in older patients. Expert Rev Anticancer Ther. 2007; 7: 285-295.
  • 3
    Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006; 91: 1513-1522.
  • 4
    Melchert M. Managing acute myeloid leukemia in the elderly. Oncology (Williston Park). 2006; 20: 1674-1682; discussion 1683-1684, 1687.
  • 5
    DeLima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol. 1996; 93: 89-95.
  • 6
    Wahlin A, Markevarn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol. 2001; 115: 25-33.
  • 7
    Mori M, Ohta M, Miyata A, et al. Treatment of acute myeloid leukemia patients aged more than 75 years: results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Leuk Lymphoma. 2006; 47: 2062-2069.
  • 8
    Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006; 106: 1090-1098.
  • 9
    Feinstein AR. Symptomatic patterns, biologic behavior, and prognosis in cancer of the lung. Practical application of Boolean algebra and clinical taxonomy. Ann Intern Med. 1964; 61: 27-43.
  • 10
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 11
    Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score [serial online]. BMC Cancer. 2004; 4: 94.
  • 12
    Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007; 109: 1376-1383.
  • 13
    Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106: 2912-2919.
  • 14
    Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007; 136: 624-627.
  • 15
    Malfuson JV, Etienne A, Turlure P, et al; Acute Leukemia French Association (ALFA). Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008; 93: 1806-1813.
  • 16
    Atlanta, Ga: Centers for Disease Control and Prevention; 2008. Available at
  • 17
    Srivastava R. The art of letting go. N Engl J Med. 2007; 357: 3-5.
  • 18
    Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336.
  • 19
    Larson RA, Dodge RK, Burns CP, et al. A 5-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood. 1995; 85: 2025-2037.
  • 20
    Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148: 839-843.
  • 21
    Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982; 60: 454-462.
  • 22
    Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004; 18: 809-816.
  • 23
    Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003; 21: 760-761.
  • 24
    Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 1268-1274.
  • 25
    Bassan R, Buelli M, Viero P, Minotti C, Barbui T. The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients. Hematol Oncol. 1992; 10: 251-260.
  • 26
    Hernandez-Boluda JC, Sierra J, Esteve J, Nomdedeu B, Montserrat E. Treatment of elderly patients with AML: results of an individualized approach. Haematologica. 1998; 83: 34-39.
  • 27
    Alymara V, Tzouvara E, Vartholomatos G, Chaidos A, Tsiara S, Bourantas KL. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001. J Exp Clin Cancer Res. 2004; 23: 447-454.
  • 28
    Orlandi E, Lazzarino M, Morra E, et al. Impact of advanced age on the management of acute nonlymphocytic leukemia: a study of 103 patients. Acta Haematol. 1990; 84: 144-148.
  • 29
    Tucker J, Thomas AE, Gregory WM, et al. Acute myeloid leukemia in elderly adults. Hematol Oncol. 1990; 8: 13-21.
  • 30
    Doubek M, Palasek I, Brychtova Y, Buchtova I, Mayer J. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy. Neoplasma. 2005; 52: 411-414.
  • 31
    Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007; 109: 5129-5135.
  • 32
    Spiess PE, Pettaway CA, Vakar-Lopez F, et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007; 110: 1729-1737.
  • 33
    Siddiqui A, Heinzerling J, Livingston EH, Huerta S. Predictors of early mortality in veteran patients with pancreatic cancer. Am J Surg. 2007; 194: 362-366.
  • 34
    Lee KH, Lee JS, Suh CW, et al. Prognostic factors of acute myelocytic leukemia: an analysis of 132 patients in a single institution. J Korean Med Sci. 1996; 11: 222-232.
  • 35
    Peterson L, Dehner LP, Brunning RD. Extramedullary masses as presenting features of acute monoblastic leukemia. Am J Clin Pathol. 1981; 75: 140-148.
  • 36
    Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001.
  • 37
    Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007; 109: 1114-1124.